

Product Data Sheet

Tocainide

Cat. No.:HY-B1798CAS No.:41708-72-9Molecular Formula: $C_{11}H_{16}N_2O$ Molecular Weight:192.26

Target: Sodium Channel

Pathway: Membrane Transporter/Ion Channel

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 125 mg/mL (650.16 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	5.2013 mL	26.0065 mL	52.0129 mL
	5 mM	1.0403 mL	5.2013 mL	10.4026 mL
	10 mM	0.5201 mL	2.6006 mL	5.2013 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	Tocainide hydrochloride is an orally activesodium channel blocker, it blocks the sodium channels in the pain-producing foci in the nerve membranes. Tocainide hydrochloride is a primary amine analog of lidocaine, can be used for the treatment of tinnitus ^{[1][2]} .
IC ₅₀ & Target	IC50: sodium channel $^{[1]}$
In Vivo	Tocainide (100 mg/kg) effectively suppresses ventricular ectopic activity in unanesthetized dogs with coronary occlusion. Termination of tocainide infusion in both digitalis toxicity and coronary occlusion models results in prompt return of ventricular ectopic activity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Alpert JS, et al. Chemistry, pharmacology, antiarrhythmic efficacy and adverse effects of tocainide hydrochloride, an orally active structural analog of lidocaine.



Page 2 of 2 www.MedChemExpress.com